↑ Rising
Business
Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial
SELLAS Life Sciences' GPS vaccine demonstrated a 41% reduction in death risk and nine-month survival benefit in a pivotal Phase 3 AML trial, sending shares up 220%.